Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes

NCT ID: NCT05221359

Last Updated: 2022-07-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-05
• Study Completion Date: 2027-04-30

Brief Summary

First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia

Conditions

Type 1 Diabetes; Type 1 Diabetes Mellitus With Hypoglycemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

test arm

All patients will be enrolled in same arm which contains the two interventions (device + drug) and follow mandatory phases of trial: screening, implantation, treatment with ExOlin, explantation.

Group Type: EXPERIMENTAL

ExOlin®

Intervention Type: DEVICE

Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.

Device explanted with a safety follow-up.

Insulin aspart

Intervention Type: DRUG

Use of NovoRapid insulin during all periods of the clinical investigations

Interventions

ExOlin®

Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.

Device explanted with a safety follow-up.

Intervention Type: DEVICE

Insulin aspart

Use of NovoRapid insulin during all periods of the clinical investigations

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adult men or women (age ≥ 18 years);

2. Diagnosis of Type 1 Diabetes (T1D) for more than 2 years at the start of screening;

3. Body mass index (BMI) > 16 kg/m2 and < 35 kg/m2;

4. Well managed intensive SubCutaneous (SC) insulin therapy, i.e. patient using for at least 3 months:

• CSII, whatever the insulin pump used, and
• Continuous Glucose Monitoring (CGM), by using Dexcom G6;

5. 7.0% < Serum HbA1c < 12.0%;

6. Patient characterized by one of the following conditions:

• Unstable diabetes/poor glycemic control, meaning patient presenting:

• at least one episode of severe hypoglycemia during the 12 months prior to study screening. Severe hypoglycemia is defined by American Diabetes Association (ADA) standards as "severe cognitive impairment requiring assistance from another person for recovery" (as per ADA's definition in "standards of care in diabetes");
• or glycemic excursions (post-prandial hyperglycemic or nocturnal hypoglycemic episodes) considered as too frequent and of high amplitude by the investigator, during the previous month;
• Presence of adverse side effects of SC insulin-therapy:

• SC insulin resistance;
• or severe acquired lipodystrophy resistant to pump treatment;
• or genetic skin atrophy or lipodystrophy.

Exclusion Criteria

1. Renal glomerular filtration rate <30 mL/min/1.73m2 as per Chronic Kidney Disease - Epidemiology Collaboration (CDK-EPI) calculation;

2. Immunocompromised patient;

3. Local or systemic acute or chronic inflammation (rheumatoid arthritis, sclerodermia);

4. Active infection or inflammation;

5. Known history of skin affliction that could impact ExOlin® tolerance;

6. Ongoing active anticoagulant therapy;

7. Severe wound healing issues;

8. Parietal reinforcement prostheses;

9. Known allergy to one of the devices' components, including known allergy to fixation systems (e.g. patch, plaster) for SC administration devices such as external pumps and CGM, or chronic allergy related to prolonged wearing of such systems;

10. Known allergy to insulin NovoRapid®;

11. Known allergy to anesthetics, or products containing iodine and its derivates, or antibiotics used during surgery (cefazolin, and combination of clindamycin and gentamycin);

12. Activity contraindicated as per external pump and CGM use recommendations;

13. Patient willing to practice activities with risks of trauma or major change in the environment pressure such as combat sport or scuba diving;

14. Cardiac condition incompatible with surgery requirements as per anesthesiologist's opinion;

15. Unstable diabetic retinopathy (as per ophthalmologist's review within 6 months before screening);

16. Current or history of unresolved malignancy within 5 years before screening (with exceptions for squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast carcinoma without lymph node metastases, well-differentiated thyroid carcinoma or other non-invasive lesion that, in the opinion of the investigator, is considered as cured with minimal risk of recurrence within 5 years);

17. Other surgical or medical condition that, in the judgment of the investigator, might warrant exclusion or be contraindicated, like for instance visual or hand-use symptoms;

18. Mental handicap or psychiatric condition incompatible with appropriate handling of devices or compliance to treatment or investigation-related tasks;

19. Known active alcohol or drug abuse;

20. Having received corticoid treatment within 4 weeks prior to enrollment;

21. Having received an investigational product within 12 weeks prior to enrollment, or currently participating in another clinical trial, with the exception of observational / non-interventional; registries, for which written prior approval of Defymed is needed;

22. Women planning for pregnancy, being pregnant or breastfeeding or unwilling to use adequate contraceptive methods for the duration of the study (oral hormonal contraceptives, implants, injectables, hormonal or copper intrauterine device, or vasectomized partner);

23. Person under guardianship, trusteeship or deprived of liberty;

24. Person not affiliated to one of the French social security systems;

25. Unwilling to give written informed consent to participation in the study, or unable to do so for psychiatric, cognitive or linguistic reasons.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Defymed

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status: RECRUITING

Countries

France

Facility Contacts

Nathalie Jeandidier, MD

Role: primary

Nathalie.jeandidier@chru-strasbourg.fr

+33 3 88 11 66 03

Other Identifiers

2020-A01763-36

Identifier Type: REGISTRY

Identifier Source: secondary_id

2020-003020-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

DEXN-T1D-2017-01

Identifier Type: -

Identifier Source: org_study_id